Scientists May Have Found a Way to Stop Zika Cold

Why scientists want to infect the world’s mosquitoes with bacteria.

Christopher Badzioch/Thinkstock

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


Mosquitoes may be small, but they pack a mean punch. Weighing in at a measly 2.5 milligrams, these buzzing arthropods are responsible for more deaths than snake bites, shark attacks, and murders combined. A whopping 725,000 people die each year from diseases transmitted by this common pest. Researchers have spent decades and millions of dollars fighting dengue, yellow fever, and chikungunya—dangerous viruses that female mosquitoes can spread in a single bite. Now—as scientists rev up efforts to tackle the worsening mosquito-borne Zika epidemic that’s rocked the Americas—some scientists are tapping into Earth’s oldest organic armies as they seek to wipe out these diseases.

In this week’s episode of the Inquiring Minds podcast, journalist and author Ed Yong explores the emerging science of the microbiome—the trillions of tiny organisms that inhabit the bodies of humans and other animals. Along the way, he tells host Kishore Hari about Wolbachia—one of nature’s most successful land-based bacteria—and its potential to aid the fight against Zika and other mosquito-borne illnesses. Wolbachia, says Yong, has “tremendous promise in bringing tropical diseases to heel.”

Wolbachia is extremely versatile; it can infect more than 40 percent of all arthropod species, including spiders, insects, and mites. Research has shown that female Aedes aegypti mosquitoes infected with the bacteria are unable to transmit common viruses, including Zika and dengue. And because Wolbachia passes from a female mosquito to her offspring, it could spread easily through a wild population. That means releasing a small batch of mosquitoes infected with the bacteria could help eradicate mosquito-borne diseases in a potentially short amount of time, says Yong. For a mosquito whose global range spans six continents—and includes a large chunk of the United States, the impact on global public health could be substantial. You can listen to the full interview below:

Despite years of research, treatments for many mosquito-borne illnesses is limited. Clinical trials for a Zika vaccine are underway, but researchers don’t expect one to be available to the public for at least 18 months. “There are no vaccines,” Yong says. “There are no good treatments for dengue. We need better ways of controlling these diseases.” Field trials of Wolbachia-carrying mosquitos have been underway in Australia since 2011, and in Brazil, Indonesia, and Vietnam since 2014. The results have shown great promise, with no ill effect on people or the environment.

Yong argues that Wolbachia is safer and more cost-effective than traditional vector control methods, such as spraying with insecticides. And unlike insecticides, bacteria are self-perpetuating. And Wolbachia doesn’t appear to affect mosquito populations, so other insects and animals that feed on these pests won’t miss a meal. “It’s not about killing mosquitos,” Yong says, “it’s about turning them into dead ends for viruses.”

To learn more about the incredible world of the microbiome, you can check out Yong’s new book, I Contain Multitudes: The Microbes Within Us and a Grander View of Life.

Inquiring Minds is a podcast hosted by neuroscientist and musician Indre Viskontas and Kishore Hari, the director of the Bay Area Science Festival. To catch future shows right when they are released, subscribe to Inquiring Minds via iTunes or RSS. You can follow the show on Twitter at @inquiringshow and like us on Facebook.

More Mother Jones reporting on Climate Desk

OUR DEADLINE MATH PROBLEM

It’s risky, but also unavoidable: A full one-third of the dollars that we need to pay for the journalism you rely on has to get raised in December. A good December means our newsroom is fully staffed, well-resourced, and on the beat. A bad one portends budget trouble and hard choices.

The December 31 deadline is drawing nearer, and if we’re going to have any chance of making our goal, we need those of you who’ve never pitched in before to join the ranks of MoJo donors.

We simply can’t afford to come up short. There is no cushion in our razor-thin budget—no backup, no alternative sources of revenue to balance our books. Corporations and powerful people with deep pockets will never sustain the fierce journalism we do. That’s why we need you to show up for us right now.

payment methods

OUR DEADLINE MATH PROBLEM

It’s risky, but also unavoidable: A full one-third of the dollars that we need to pay for the journalism you rely on has to get raised in December. A good December means our newsroom is fully staffed, well-resourced, and on the beat. A bad one portends budget trouble and hard choices.

The December 31 deadline is drawing nearer, and if we’re going to have any chance of making our goal, we need those of you who’ve never pitched in before to join the ranks of MoJo donors.

We simply can’t afford to come up short. There is no cushion in our razor-thin budget—no backup, no alternative sources of revenue to balance our books. Corporations and powerful people with deep pockets will never sustain the fierce journalism we do. That’s why we need you to show up for us right now.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate